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ABSTRACT 
 
We describe a tandem RNA isolation procedure (TRIP) that enables purification of in vivo 
formed messenger ribonucleoprotein (mRNP) complexes. The procedure relies on the 
purification of polyadenylated mRNAs with oligo(dT) beads from cellular extracts, followed 
by the capture of specific mRNAs with 3'-biotinylated 2'-O-methylated antisense RNA 
oligonucleotides, which are recovered with streptavidin beads. TRIP was applied to isolate in 
vivo crosslinked mRNP complexes from yeast, nematodes and human cells for subsequent 
analysis of RNAs and bound proteins. The method provides a basis for adaptation to other 
types of polyadenylated RNAs, enabling the comprehensive identification of bound 
proteins/RNAs, and the investigation of dynamic rearrangement of mRNPs imposed by cellular 
or environmental cues.  
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1. Introduction 
Messenger RNAs (mRNAs) are dynamically controlled by hundreds of RNA-binding 
proteins (RBPs) and non-coding RNAs such as microRNAs (miRNAs) [1, 2]. Thereby, RBPs 
and associated miRNAs bind to distinct elements in the mRNA, forming so-called 
ribonucleoprotein (RNP) complexes, which control the localization, translation and decay of 
mRNAs [3, 4]. Thus, the isolation and molecular characterization of RNPs is fundamental to 
understand the fate of mRNAs and post-transcriptional gene control.  
 Several complementary protein and RNA "centric" approaches have been developed to 
isolate and characterize RNA-protein complexes (reviewed in [5, 6]). The protein centric 
approach relies on the ability to purify a particular RBP or a complex thereof, followed by 
identification of the bound RNAs with DNA microarrays or high-throughput sequencing. 
Thereby, RBPs are isolated from cellular extracts with specific antibodies that selectively 
recognize an epitope of a constituent protein or via affinity purification of epitope tagged 
proteins. Whereas RBP immunoprecipitation followed by microarrays or sequencing (RIP-
Chip/RIP-seq) involves the purification of native RNA-protein complexes under physiological 
conditions, the more elaborate crosslinking immunoprecipitation (CLIP) or photoactivatable 
ribonucleoside–enhanced crosslinking and immunoprecipitation (PAR-CLIP) procedures 
include the crosslinking of RNA-protein interactions in vivo upon exposure of cell to ultraviolet 
(UV)-light, followed by purification of the RBP and mild RNA digestion to obtain a footprint 
of the RBP binding site on the RNA [5, 6]. 
 Conversely, the RNA centric approaches rely on the purification of RNA followed by 
the analysis of the associated proteins or RNAs. Recently, mRNA-protein interactome capture 
to profile the set of proteins bound to polyadenylated (poly[A]) RNAs across different 
organisms has become popular [7-14]. These studies confirmed hundreds of previously known 
RBPs, but likewise identified many novel RBPs, such as metabolic enzymes and others, whose 
function in post-transcriptional gene regulation is still enigmatic [11, 12, 14, 15]. Nevertheless, 
the mapping of the RBP repertoire assembled on particular transcripts in vivo is still a 
challenge. Therefore, a particular mRNA shall be captured and bound proteins and RNAs 
identified with mass-spectrometry (MS)/ immunoblot analysis and sequencing, respectively. 
Currently, most applications to tackle this issue rely on the use of RNA-tags (=aptamers) that 
either bind to aminoglycosidic antibiotics such tobramycin or streptomycin [16-19] or to 
proteins with high affinity. Regarding the latter, most widely used are the coat proteins from 
the R17/MS2 bacteriophage and streptavidin S1, a bacterial protein, both of them interacting 
with short hairpin RNA structures [20-24]. The repeats of the MS2 or S1 binding RNA stem 
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loop are appended to a RNA of interest and the tagged RNA complex is then purified by 
coupling of the respective protein to a solid support or resin [20-24]. While these indirect RBP-
mediated approaches are relatively versatile and represent an efficient tool for RNA 
localization studies [25-27], a major drawback is the indirect nature of the interaction, making 
it prone to artefacts resulting from the ectopic expression of the protein, cross-reactivity with 
untagged RNAs, interference with native RNP formation, and unspecific interactions. 
Importantly, it requires engineering of the RNA under investigation and thus cannot be applied 
to recover native mRNAs. Nevertheless, aptamer based approaches have been implemented 
successfully to enrich well-expressed RNP complexes, such as the spliceosome or ribosomal 
particles, whereas broader application for purification of mRNAs has been scarce. 
 Besides aptamers, antisense oligonucleotide (ASO) probes such as biotinylated 2’-O-
methylated RNA oligos have been implemented early on for the direct purification of well-
expressed RNP complexes, such as the spliceosome [28] and telomerase [29]. More recently, 
modified RNA oligos were used to capture long ncRNAs (lncRNAs) from human cells [30]; 
whereas an array of long antisense DNA oligos were applied to capture Xist, a nuclear long 
ncRNA [31-32]. However, the recovery of endogenously expressed mRNAs with antisense 
oligos is still not well established. 
 Here we describe the tandem RNA isolation procedure (TRIP), a two-step procedure 
based on antisense DNA/RNA oligonucleotides to recover native mRNA-protein complexes 
from cells with high selectivity. TRIP is versatile as it was tested on particular mRNAs 
expressed in yeast, nematodes, and human cells, enabling further analysis of in vivo formed 
mRNA-protein complexes with biochemical means. In the following, we provide a detailed 
description of TRIP, whereby focus is given on the recovery of a particular mRNAs from 
poly(A) RNA with biotinylated 2'-methoxy RNA oligonucleotides.  
 
2. Description of the tandem RNA isolation procedure (TRIP) 
 
TRIP is based on the specific hybridization of nucleotide sequences in the target RNA with 
modified antisense DNA/RNA oligonucleotides (Fig. 1). The first step involves the enrichment 
of poly(A) RNAs from a cell lysate using oligo(dT)25 beads, followed by a second purification 
step that relies on the capturing of particular mRNAs from poly(A) RNAs using 3'-biotinylated 
2'-O-methylated RNA ASOs. The bound proteins or associated RNAs on the captured mRNA 
are then identified by immunoblot and reverse transcription (RT)-PCR, respectively. In 
principle, the method could be extended towards the global analysis of protein and RNAs by 
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mass-spectrometry and RNA sequencing, respectively; however, we wish to note that the set-
up described herein has been designed for confirmatory purposes and was not tested for global 
discovery of bound proteins and/or associated RNAs, which may require substantial larger 
amounts of starting material.  
 The rationale to perform the sequential isolation of a particular mRNA, rather than a 
direct single step purification, is based on our attempts using either aminoglycoside-based RNA 
aptamers or ASOs to capture endogenously expressed mRNAs from yeast and C. elegans 
cellular extracts. Thereby, a major problem we encountered was related to the inefficient 
capture of respective mRNAs from crude cell extracts and contamination from unrelated 
proteins in the RNA isolates. Therefore, we reasoned that reducing the complexity of the 
samples upon capture of particular mRNAs by a first enrichment of poly(A) RNAs, which 
recovers mRNAs although poly(A) ncRNAs may also be present, could substantially improve 
recovery and specificity of the procedure. We also found that contamination with non-target 
mRNAs is less prevalent with TRIP. 
 To establish TRIP, we selected three different mRNAs from three different organisms: 
the endogenously expressed mRNA for PFK2 from the yeast Saccharomyces cerevisiae and 
cep-1 from the nematode Caenorhabditis elegans, as well as a reporter mRNA (pGL3-LUC-
p27-3'UTR) bearing the 3'UTR sequence of human p27/CDKN1B mRNA fused to a luciferase 
reporter, which was transiently expressed in human HEK293 cells. We have chosen these 
mRNAs for investigation as selective mRNA-protein interactions have been reported 
previously, providing the opportunity to monitor the presence of respective proteins during the 
establishment of the procedure. The proteins used to validate this technique are: Pfk2 protein 
from yeast, which binds selectively to mRNAs coding for glycolytic enzymes, including PFK2 
mRNA in a ribosome independent manner [11]; C. elegans GLD-1, a canonical RBP that binds 
to sequences located in the 3'UTR of cep-1 mRNA and thereby regulates translation [33]; and 
HuR, which plays crucial roles in the regulation of mRNA stability and translation of 
p27/CDKN1B mRNA, coding for an important tumour suppressor protein [34].  
 
2.1. Design of antisense RNA oligonucleotides  
We favoured the use of modified RNA oligos as they allow for more stringent 
conditions during washing procedures and 2′-O-methyl groups offer great stability against 
general base hydrolysis and nucleases. Such RNA oligos have been previously applied to enrich 
ncRNAs from human cell extracts [30]; nevertheless, DNA oligos may also be feasible but 
have not been tested explicitly by us [35]. We thus designed several ASOs of ~21-24 
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nucleotides (nts) in length that specifically anneal with the desired target in the 3’ untranslated 
regions (UTR) (Table 1). We also made oligos annealing in the open reading frame (ORF) but 
they generally performed less well and are thus not further described herein. Due to the property 
of the oligo to anneal with complementary single strands, ASOs were preferentially designed 
to anneal in RNA loops instead of extended double-stranded RNA regions and stems as 
predicted in silico with RNA secondary structure predictions programmes 
(http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi [36]. Additionally, the analysis with Basic 
Local Alignment Search Tool (BLAST, blast.ncbi.nlm.nih.gov/Blast.cgi) showed no 
significant alignment to other mRNA sequences that could lead to cross-hybridization. We 
wish to note that even a partial continuous alignment encompassing 8-10 nts could potentially 
lead to cross-hybridization and recovery of other mRNA (data not shown). After selection of 
several suitable ASOs for each mRNA target (we propose to design at least three ASO per 
RNA), the ASOs were synthesized bearing 2′-O-methyl groups, an analogue that offers 
stability against general base hydrolysis and nucleases, and a biotin moiety at the 3’ end to 
facilitate capturing of ASOs with streptavidin beads. 
 
2.2 Testing selectivity of ASOs with total RNA 
 To test the suitability of the ASOs for hybridization and isolation of respective mRNAs, 
biotinylated RNA oligos were coupled to streptavidin-conjugated paramagnetic beads and 
incubated with total RNA isolated from non-crosslinked organisms/cells. This approach 
excludes the presence of other cellular molecules such as RBPs that may mask the annealing 
site in the target mRNA. The amount of ASO that can be coupled to streptavidin beads was 
then determined empirically by titrating increasing amounts of ASOs to a fixed amount of 
streptavidin beads (Fig. 2A). We found that ~200 pmol (= 2 M solution) of ASO could be 
efficiently coupled to 30 µl of streptavidin magnetic beads (M280, Invitrogen, 11205D) within 
10 min at room temperature. 
The ASO-coupled beads were further blocked with buffer containing an excess of E. 
coli derived tRNA (Roche, 10109550001) to saturate the matrix and to avoid unspecific 
binding of RNA. After several washes, total RNA was added to the ASO-coupled streptavidin 
beads and incubated for 5 min at 70 ºC and cooled down slowly to room temperature to enable 
hybridization between the ASOs and the target mRNA. After washing, the RNA was eluted 
from the beads with low salt buffer (10 mM Tris-HCl, pH 7.5) and recovered mRNAs identified 
with RT-PCR. In the frame of these experiments, we realized that washing of beads at lower 
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temperatures (20 - 40 ºC) could lead to the recovery of unwanted non-target mRNAs, as 
exemplified with cep-1 mRNA (target) and the non-target pgk-1 control mRNA (Fig. 2B). As 
expected, increasing the washing temperature to 50 - 55 ºC significantly reduced contamination 
of the pgk-1 non-target mRNA in the eluate but only marginally diminished the recovery of 
target cep-1 mRNAs (Fig. 2B). Furthermore, we observed a progressive decrease in the 
capturing of target mRNAs at temperatures above 55 ºC. We thus affirm a critical role for 
washing at elevated temperatures, which is nevertheless below the calculated melting-
temperatures for ASOs (~65 ºC).  
We also tested the effect of different salt concentrations in the wash buffer at 55 ºC 
(Fig. 2C). As shown for the yeast PFK2 target mRNA and the non-target PFK1 mRNA, we 
commonly observed that lowering the concentration of salt (NaCl) in the wash buffer reduced 
the capture of non-target mRNAs to below detectable levels, but also substantially reduced the 
amount of target mRNAs (~15% of the input). Salt concentration at near physiological levels 
(~150 mM NaCl) performed best: about 75% of target mRNAs could be recovered and this 
exceeded the recovery of non-target mRNAs by at least 5-fold.  
To test the versatility of the optimized procedure, we monitored the capture of selected 
target mRNAs and non-target mRNAs from yeast (S. cerevisiae), nematodes (C. elegans) and 
human total RNA that was isolated from non-crosslinked cells/organisms (Fig. 2D). In all 
cases, we found that target mRNAs could be recovered with high-selectivity above non-target 
mRNAs with the finally selected ASOs (Table 1). Furthermore, neither mRNAs could be 
detected on beads in the absence of ASOs, demonstrating appropriate blocking procedures that 
avoid unspecific binding of RNAs to beads. We wish to note, that these experiments were 
useful for the evaluation of different ASOs designed for the same target mRNAs, as different 
oligos showed great variation in the recovery of mRNA targets (up to 5-fold) and 
contamination with unrelated mRNAs (see Troubleshooting).  
 
2.3. Applying TRIP to enrich in vivo crosslinked RNP complexes 
 After testing ASOs for their suitability to recover the respective mRNA target from 
total RNAs, we next applied the optimized conditions to recover particular mRNAs from 
extracts of UV-crosslinked cells (Fig. 1). The irradiation of cells with UV light (254 nm) 
crosslinks RNA-protein interactions in vivo, therefore allowing the application of stringent 
wash conditions during purification. Nonetheless, although not explicitly tested, TRIP may 
also work without UV-crosslinking of cells for purification of active mRNPs applying less 
stringent physiological buffers. However, this bears potential for re-arrangement of proteins 
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and/or RNAs with the target mRNA in cell-lysates, which should be taken into consideration. 
To evaluate selective purification of poly(A) mRNAs during the 1st step of the procedure, we 
added an excess of polyadenylic acids as competitor to each extract before mRNA isolation 
[11]. On the one hand, we then monitored the presence of the target mRNA targets and non-
target mRNA controls by RT-PCR across the procedure (Fig 3A). On the other hand, we 
examined the presence of RBPs known to interact with respective mRNA targets by 
immunoblot analysis (Fig. 3B).  
 The mRNA targets from yeast, nematodes and human cells were selectively recovered 
from crosslinked cells across the two steps of the procedure (Fig. 3A). During the first step, the 
addition of poly(A) to extracts completely abolished the recovery of mRNAs and interacting 
proteins with oligo(dT)25 beads, showing specificity for enrichment of poly(A) mRNAs. In the 
second step, the respective mRNA targets were preferentially captured over non-target control 
mRNAs with ASOs (on average ~40% of target mRNAs were recovered from the input). In 
yeast, PFK2 mRNA was enriched in final eluates whereas the non-target mRNAs PFK1 and 
ACT1 were not enriched; in nematodes, cep-1 mRNA was enriched at least 3-fold compared to 
pgk-1 and mpk-1 unrelated control mRNAs; and in HEK293 cells, mRNAs corresponding to 
the transiently transfected reporter harbouring the p27 3'UTR were detected, whereas the non-
target ẞ-tubulin was not. As seen in test experiments with total RNA, neither mRNA was 
identified on beads in the absence of ASOs, demonstrating appropriate blocking procedures 
that avoid unspecific binding of RNAs. We wish to note that the recovery of non-target mRNAs 
may be more prevalent in the crosslinked samples compared to test experiments with non-
crosslinked total RNAs as exemplified for cep-1 mRNAs (compare Fig. 3A and Fig. 2D). The 
reason for these differences is not known but could be manifold e.g. the masking of the binding 
site by other mRBPs in crosslinked samples, or the presence of RNA structures in vivo that 
could partially anneal with the chosen oligonucleotides. 
We also followed the presence of RBPs that were expected or known to interact with 
corresponding mRNA targets by immunoblot analysis (Fig. 3B). We found that endogenously 
tandem-affinity purification (TAP)-tagged Pfk2 was recovered with PFK2 mRNA capture with 
ASOs. This result corroborates our earlier finding that yeast Pfk2p interacts with PFK2 
mRNAs, suggesting potential post-transcriptional mediated auto-regulatory control of its 
expression [11]. Similarly, GLD-1 was recovered with cep-1 mRNA in C. elegans, and HuR 
was captured with reporter mRNAs bearing the 3'UTR of p27/CDKN1B mRNA from human 
HEK293 cells. To ensure that observed associations were genuine we also tested for non-RBPs 
in samples. As expected, neither Act1p from yeast S. cerevisiae, nor CYT-C from C. elegans 
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and human ẞ-actin were enriched with respective mRNAs (Fig. 3B). These results show that 
TRIP is a valuable to enrich particular mRNP complexes from different species. 
 
3. Detailed protocol 
 
3.1 Test the binding of biotinylated ASOs to streptavidin magnetic beads 
The biotinylated ASOs (Table 1) were diluted in 100 µl of binding and wash (B&W) 
buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5 mM EDTA, pH 8.0) and incubated with 
30 µl (50% slurry) streptavidin coupled magnetic beads (M280, Invitrogen, 11205D) for 10 
min at room temperature with constant shaking (500 rpm). Concentration of RNA was 
measured by optical density (OD) at 260 nm with a Nanodrop ND-2000 device. 
 
3.2. Capture of mRNAs with ASOs from total RNA 
Total RNA from yeast S. cerevisiae and C. elegans cells was isolated according to 
standard procedures [37, 38]. Total RNA from HEK293 cells was isolated with the RNA 
Miniprep Kit (Zymo research, R1064). 
To capture selected mRNAs from purified total RNA with ASOs (Fig. 2), 30 µl (50% 
slurry) of streptavidin coupled paramagnetic beads (M280, Invitrogen, 11205D) were added to 
a 1.5 ml eppendorf tube and equilibrated for 1 h in 1 ml of B&W buffer supplemented with 0.1 
mg/ml E. coli tRNA (Sigma, 10109550001) in a rotatory wheel. The beads were recovered 
with a magnet and resuspended and washed three times with 750 µl B&W buffer at 25 ºC. 200 
pmol of respective ASO supplied in 100 µl B&W was added to the equilibrated beads and 
incubated for 10 min. The beads were subsequently washed three times with B&W buffer to 
remove excess ASOs. 600 ng of total RNA supplied in 100 µl B&W buffer was added to the 
ASO-coupled streptavidin beads and incubated for 5 min at 70 ºC in a thermoshaker incubator 
(Peqlab). The tubes were slowly cooled down to 25 ºC and further kept at 25 ºC for 2 h with 
shaking (1,000 rpm). Finally, the beads were washed three times in B&W buffer at 55 ºC and 
RNA eluted in 20 µl of 10 mM Tris-HCl, pH 7.5 at 90 ºC for 10 min. Specific mRNA were 
identified by RT-PCR with primers listed in Table 1 (see below for details). 
 
3.3. First step: UV crosslinking of cells and purification of poly(A) mRNAs 
 UV crosslinking of cells, extract preparation and the isolation of poly(A) RNAs from 
yeast diploid cells (strain derivate of BY4743; MATa/α his3Δ1/his3Δ1 leu2Δ0/leu2Δ0 
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LYS2/lys2Δ0 met15Δ0/MET15 ura3Δ0/ura3Δ0 PFK2:TAP/PFK2) and C. elegans (Bristol N2 
synchronized at larvae stage 4) was performed as described previously [11].  
 HEK293 cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) containing 
high glucose and pyruvate (Sigma, #41966) and supplemented with 100 U/ml penicillin, 100 
μg/ml streptomycin (Sigma, P4333), and 10 % FBS (Sigma, F7524). The cells were grown in 
100 × 20 mm standard tissue culture dishes (Falcon, 353003) in a humidified incubator at 37°C 
and 5% CO2. 10
7 cells (>70% confluent) were transiently transfected with 2 µg of pGL3-
luciferase-p27-3’UTR plasmid (I.V., A.P.G., unpublished) with 20 µl lipofectamine 2000 
(Invitrogen, 11668027) and placed in an incubator at 37 °C for 48 h before harvesting. Cells 
were washed twice with 10 ml of pre-warmed PBS (Sigma, 59321C) and after removal the 
final rinse, 6 ml of PBS was added. For crosslinking of protein-RNA complexes in vivo, the 
cells were exposed to UV light (254 nm) at 150 mJ/cm2 in a Stratalinker 1800 (Stratagene). 
The cells were then scraped from the plate and transferred to a 15 ml Falcon tube and 
centrifuged at 235g for 10 min at 4 °C. PBS was removed and 2 ml of lysis buffer (100 mM 
Tris-HCl, pH 7.5, 500 mM LiCl, 10 mM EDTA, 1% Triton X-100, 5 mM DTT, 20 U ml-1 
DNase I (Promega, M6101), 100 U ml-1 RNasin (Promega, N2611), complete EDTA-free 
protease-inhibitor cocktail (Roche, 11836170001) was added to the pellet [11]. The cell lysate 
was then subjected to three rounds of sonication (Soniprep150, MSE) consisting of 20 s bursts 
at 10 amplitude microns and 30 sec cooling periods on ice between bursts to complete lysis 
and to fragment DNA. The lysate was finally centrifuged at 15,000g for 10 min at 4 °C, and 
the supernatant (= extract) collected for poly(A) mRNA isolation. Protein concentration of the 
extract was determined with the Bradford assay (BioRad, 5000205) with BSA as a reference 
standard. Poly(A) RNAs were isolated from 4 mg of HEK293 cell extracts upon incubation 
with 1 mg of oligo(dT)25 Dynabeads (Life Technologies, 61011) in lysis buffer according to 
our published yeast protocol [11]. 
 
3.4 Second step: Capturing of specific mRNAs with 3'-biotinylated 2'-methoxy modified 
antisense RNAs 
 ~35 µg (protein) of the eluate from the first step (~15 µg poly(A) RNA) was supplied 
in 100 µl B&W buffer and transferred to a LoBind 1.5 ml eppendorf tube (Eppendorf, 
022431081). 200 pmol of the corresponding ASO was added, mixed and incubated at 70 ºC for 
5 min in a thermoblock. Subsequently, the block was removed from the device and placed at 
room temperature (~25 °C) to cool down slowly. 30 µl (50% slurry) of blocked streptavidin 
magnetic beads (see above) were added, and the mixture was incubated for 30 min at 25 °C 
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with constant shaking at 1,000 rpm. The beads were retrieved using a magnet and the 
supernatant was collected for reference. The beads were then washed three times with 750 µl 
B&W buffer at 55 ºC. Finally, 50 µl of B&W buffer was added and the sample split: 20 µl 
(2/5) for RNA and 30 µl (3/5) for protein analysis. To recover the RNA, the B&W buffer was 
removed and beads were resuspended in 20 µl 10 mM Tris-HCl, pH 7.5 and incubated at 90 ºC 
for 10 min to elute RNA from beads. For protein analysis, the B&W buffer was removed and 
beads were resuspended in 20 µl Laemmli buffer (12.5 mM Tris-HCl, pH 6.8, 4% sucrose, 
1.4% SDS, 1% β-mercaptoethanol, 0.004% bromophenol blue) and denatured at 95 ºC for 5 
min. 
 
3.5 RNA analysis  
 To perform RT, 9.4 μl of the eluates from the 1st and 2nd step of TRIP or 500 ng of total 
RNA isolated from extracts (input) were combined with 2.5 μM of oligo(dT)18 and 30 μM of 
random hexamer primers and additional compounds of the Transcriptor High Fidelity cDNA 
Synthesis Kit in a final volume of 20 μl according to the manufacturer’s instructions (Roche, 
05091284001). PCR was further performed with 1 μl of complementary DNA (cDNA) for 10 
min at 95 °C, 28-35 cycles at 95 °C for 30 sec, 59 °C for 30 sec, 72 °C for 30 sec, and 8 min at 
72 °C with the primers listed in Table 1. PCR products were resolved on a 2% agarose gel and 
visualized with peqGreen DNA/RNA dye (Peqlab, 37-5000). Gels were recorded with a 
FluorChem (Alpha Innotech) and quantified with Image J software.  
 
3.6 Immunoblot analysis 
 Proteins were resolved on 4–15% SDS polyacrylamide gels and transferred to 
polyvinylidene difluoride (PVDF) membranes (Thermo Scientific Pierce, 88518). Membranes 
were blocked in PBS with 0.1% Tween-20 and 5% low fat milk, probed with the indicated 
antibodies and horseradish peroxidase (HRP)-coupled secondary antibodies, and developed 
with the Immobilon Western Chemiluminescent HRP Substrate (Millipore, WBKLS0500). 
The following antibodies were used: mouse anti–Act1 (1:2,500; MP Biomedicals, 0869100) 
for detection of yeast Act1p, mouse anti–actin (1:2,000; Sigma, A1978) for detection of human 
actin, mouse anti–GLD-1 (1:50, [39]), mouse anti–HuR (1:500; Santa Cruz, sc-5261), mouse 
anti–CYC-1 (1:1,000; Invitrogen, 456100), peroxidase anti-peroxidase soluble complex 
(1:5,000; Sigma, P1291) to detect Pfk2:TAP, and HRP-conjugated sheep anti-mouse IgG 
(1:5,000; Amersham, NXA931). 
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4. Troubleshooting 
 
4.1 Inefficient recovery of target mRNAs with ASOs from total RNA and/or crosslinked samples 
 We recommend testing several ASOs (at least three) that anneal in different regions of 
the transcript. In our case, we designed 2-3 ASOs of the same length that anneal in the 3'UTR 
or in the coding sequence of the respective mRNA target, and we noticed that each ASO 
exhibited different efficiency for recovery of the corresponding target. At the end, we found 
that ASOs annealing in the 3'UTRs performed better compared to the ones designed to coding 
sequences, maybe due to increased accessibility of binding sites in UTRs. We also observed 
repeatedly that the combination of several ASOs could lead to increased contamination from 
highly expressed non-target mRNAs and could decrease pull-down efficiency of the mRNA 
target.  
 It is also essential to control the integrity of the RNA in crosslinked samples as RNA 
degradation could lead to substantial loss of the recovery efficiency. For instance, care should 
be taken with UV-crosslinking as overexposure may lead to RNA degradation. Therefore, an 
analytical sample of the cell-lysate should be taken and RNA visualized on an agarose gel to 
control the integrity of total RNA. We also recommend treating the equipment with RNase 
decontamination solution (RNaseZap®), and the use of RNase-free consumables (tips, tubes). 
 Finally, we noticed the order of the addition of the components (sample-ASO-beads) 
was crucial for efficient recovery of RNAs from the crosslinked samples. In our hands, the 
incubation of the poly(A) enriched fraction with ASOs prior to the addition of streptavidin 
beads performed better as compared to the application of ASO-coupled beads to the sample. 
Possibly, the unbound oligos are kinetically favoured and have better access to sequences 
within structured RNA molecules. 
 
4.2 Contamination with unrelated RNAs or proteins in the affinity isolates 
Whereas the design of the ASOs is key for successful isolation of particular mRNAs as 
outlined above, other factors can also have significant impact in determining selectivity. For 
instance, it is essential to control the temperature of the wash buffers. We recommend to pre-
heat the wash buffers to the desired temperature and to add them quickly to the sample, which 
should be kept in a thermoshaker. Furthermore, extended incubation of extracts with ASOs 
may lead to the increased recovery of un-related mRNAs and thus, the incubation time during 
annealing should be kept as short as possible. In any case, the selectivity could be further 
controlled by competition experiments (e.g. addition of competing oligos). 
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In case of a general contamination with unrelated RNAs, which is not necessarily 
related to the ASO, the implementation of extensive blocking procedures using BSA and/or 
tRNA according to the bead type specifications can reduce unspecific binding to beads. Of 
note, the use of Lo-bind tubes is beneficial for working with low-amounts of samples, and it 
further reduces general background.  
  
5. Concluding remarks 
 
TRIP permits the isolation of factors bound to particular mRNAs in vivo applying biochemical 
means. While the method has been applied to confirm the interaction of previously known 
RBPs with mRNA targets, up-scaling of the procedure could enable the systematic analysis of 
bound proteins and/or RNAs with MS or RNA sequencing, respectively. Although the RNAs 
studied here were mRNAs and the RBPs associated with it, TRIP may well be applicable to 
study other types of poly(A) RNAs, such as cytoplasmic ncRNAs. Hence, our method 
complements a previously established approach to capture nuclear lncRNAs: Xist was 
recovered from nuclear extracts prepared from 200-800 million of crosslinked cells with an 
array of long (90-mer) biotinylated DNA oligonucleotides spanning the entire transcript [31, 
32]. TRIP may also be adapted for investigation of mRNA-RNA interactions, e.g. to identify 
the set of miRNAs that regulate a particular target transcript. Importantly, TRIP can be applied 
to specifically target native mRNAs without the requirement of genetic manipulation of the 
respective gene of interest. This is in stark contrast to currently used methodologies that use 
RNA aptamers to tag the respective mRNA of interest. Nevertheless, we wish to note that TRIP 
prerequisites the careful design and evaluation of the ASO for isolation of target mRNAs to 
exclude crosshybridization with related sequences (non-targets). Furthermore, RBPs/ncRNA 
may cover the ASO binding site in the mRNA in vivo, making it inaccessible for annealing 
with the ASOs. In this regard, we observed repeatedly that the combination of several ASOs 
could be detrimental as it can lead to increased contamination from highly expressed non-target 
mRNAs and decrease pull-down efficiency of the mRNA target. We thus favour the use of two 
sequentially arrayed ASOs (oligo(dT) and one specific ASO) as implemented in TRIP. In light 
of the rapidly increased recognition of post-transcriptional gene control, we believe that TRIP 
will be a formidable tool to investigate the dynamic rearrangement of RNP complexes within 
cells upon intracellular and environmental cues, and to understand its impact in health and 
disease.  
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Figure legends 
 
Fig. 1. Schematic view of TRIP. RNP complexes are crosslinked in vivo by UV irradiation. In 
a first step, poly(A) RNA-protein complexes are captured with oligo(dT)25 beads under 
stringent washing conditions. In a second step, the target mRNP complex is specifically pulled 
out with biotinylated anti-sense RNA oligonucleotides and streptavidin beads. The isolated 
mRNPs are analysed by RT-PCR and immunoblot/mass-spectrometry (MS) to identify RNAs 
and proteins, respectively. 
 
Fig. 2. Testing the capture of specific mRNAs from total RNA isolated from non-crosslinked 
cells/organisms with antisense 3'-biotinylated 2'-methoxy RNA capture probes. (A) Time 
course representing the fraction of unbound ASO upon incubation with 30 μl of streptavidin 
beads. Different lines represent different starting amounts of ASOs added to the beads. (B) 
Fraction of cep-1 ASO bound mRNAs at different wash temperatures. Pgk-1 is a non-target 
(control) mRNA. (C) Fraction of PFK2 ASO bound yeast mRNA at different salt (NaCl) 
concentration in the wash buffer. PFK1 is a non-target (control) mRNA. (D) Agarose gel 
showing products from RT-PCR reactions for detection of mRNAs (right) captured with 
indicated ASOs from yeast S. cerevisiae, C. elegans, and human HEK293 (H. sapiens) total 
RNA. Input, total RNA; Sn, supernatant after incubation with ASOs; E, eluates from beads; 
Ctrl, control experiment performed in parallel without addition of ASOs.  
 
Fig. 3. Isolation of specific mRNA-protein complexes from cell extracts of UV-crosslinked 
organisms or human cells with TRIP (A) Agarose gel showing products from RT-PCR 
reactions for detection of mRNAs (right) captured with oligo(dT) and indicated ASOs from S. 
cerevisiae, C. elegans and human cell extracts. Input, total RNA isolated from crosslinked 
cells/organisms; Ctrl, control experiment (Ctrl) without addition of ASO. Poly(A), addition of 
competitor poly(A) to evaluate the specificity of mRNA isolation. (B) Immunoblot analysis for 
detection of mRNA-bound proteins with specific antibodies (right). The following amounts 
were loaded on the gel: 0.1%, 2.5% and 1% of the yeast, nematode and human extract (input); 
10%, 10% and 5% of the yeast, nematode and human oligo(dT) isolates; and 66% of the ASO 
and Ctrl eluates. Markers with molecular weights (MW) are indicated in kilodaltons (kDa). 
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Table 1: Oligonucleotide sequences.  
Primer name Sequence (5'-3') Target Length  
Pfk2_Fwd GTGTTAAGGGTTCACATGTCG PFK2 S. cerevisiae 133 bp 
Pfk2_Rev CTTCCAACCAAATGGTCAGC PFK2 S. cerevisiae 133 bp 
Pfk1_Fwd GGTGATTCTCCAGGTATGAATG PFK1 S. cerevisiae 97 bp 
Pfk1_Rev CTTCGTAACCTTCGTAAACAGC PFK1 S. cerevisiae 97 bp 
Act1_Fwd GTCTGGATTGGTGGTTCTATC ACT1 S. cerevisiae 85 bp 
Act1_Rev GGACCACTTTCGTCGTATTC ACT1 S. cerevisiae 85 bp 
Cep1_Fwd CGATGAAGAGAAGTCGCTGT cep-1 C. elegans 110 bp 
Cep1_Rev ATCTGGGAACTTTTGCTTCG cep-1 C. elegans 110 bp 
Pgk1_Fwd GCGATATTTATGTCAATGATGCTTTC pgk-1 C. elegans 74 bp 
Pgk1_Rev TGAGTGCTCGACTCCAACCA pgk-1 C. elegans 74 bp 
Mpk1_Fwd TGCTCAGTAATCGGCCATTG mpk-1 C. elegans 74 bp 
Mpk1_Rev TCCAACAACTGCCAAAATCAAA mpk-1 C. elegans 74 bp 
p27_Fwd 
TTTAAAAATACATATCGCTGA 
CTTCATGG 
p27  
H. sapiens 
212 bp 
p27_Rev 
CAAAGTTTATGTGCTACATAA 
AAGGTAAAAA 
p27  
H. sapiens 
212 bp 
Luc_Fwd AATGGCTCATATCGCTCCTGGAT Luciferase P. pγralis 117 bp 
Luc_Rev TGGACGATGGCCTTGATCTTGTCT Luciferase P. pγralis 117 bp 
β-TUB_Fwd CTGAACCACCTTGTCTCAGC β-TUB H. sapiens 136 bp 
β-TUB_Rev AGCCAGGCATAAAGAAATGG β-TUB H. sapiens 136 bp 
PFK2 ASO GUUUCAUGGGGUAGUACUUGU 
3' UTR PFK2  
S. cerevisiae - 
cep-1 ASO GUGAGAAAUGCGGUGCUUUGAAA 
3' UTR cep-1  
C. elegans - 
p27 ASO UCAUACCCCGCUCCACGUCAGUU 
3' UTR p27 
 H. sapiens - 
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A versatile tandem RNA isolation procedure for capturing in vivo formed mRNA-
protein complexes 
 
Highlights 
 
 Tandem RNA isolation procedure (TRIP) to enrich particular mRNAs and 
bound proteins 
 
 TRIP uses modified antisense RNA oligonucleotides annealing with sequences 
in mRNA 
 
 Adaptable to native cells/organism without requirement for genetic 
engineering 
